8-K
filed March 20, 2026, 7:59 PM ET
ticker RGNX
CIK 0001590877
litigation
confidence high
sentiment neutral
materiality 0.60
REGENXBIO settles GSK sublicense fee dispute for $10M
REGENXBIO Inc.
- Company will pay $10.0M to GSK within 3 business days for alleged underpayment of sublicense fees.
- Settlement includes mutual releases of past claims and certain future claims under the 2009 license agreement.
- Company retains existing allocation methodology for future sublicense fee payments to GSK.
- Dispute covered sublicense fees and royalties on amounts received from sublicensees.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001193125-26-117913
- form_type
- 8-K
- ticker
- RGNX
- cik
- 0001590877
- company_name
- REGENXBIO Inc.
- filed_at
- 2026-03-20T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:35.566938+00:00
- generated_at
- 2026-05-15T09:29:20.796145+00:00
- sec_items
- ["1.01"]
- event_type
- litigation
- sentiment
- neutral
- materiality_score
- 0.6
- calibrated_materiality_score
- 0.6
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001193125-26-117913
- json_url
- https://secwatch.observer/filing/0001193125-26-117913.json
- markdown_url
- https://secwatch.observer/filing/0001193125-26-117913.md
- text_url
- https://secwatch.observer/filing/0001193125-26-117913.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1590877/000119312526117913/0001193125-26-117913-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1590877/000119312526117913/rgnx-20260318.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
SGRP
SPAR Group settles arbitration with founder Robert Brown; extends CIC agreement to 2028
SPAR Group, Inc.
May 5, 2026, 7:59 PM ET
litigation
Items 1.01, 9.01
same fact type: material_agreement
same SEC item: 1.01
same event type: litigation
similar materiality
This filing
On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”).
Comparable filing
On May 1, 2026, the Company entered into a Settlement Agreement and Release with Robert G. Brown and SPAR Business Services, Inc. allowing for a dismissal of the Arbitration action between the Company and Robert G. Brown.
Filing page
SEC filing
MCHX
Marchex settles civil lawsuit for $2M, payments spread over 13 months
MARCHEX INC
April 15, 2026, 7:59 PM ET
litigation
Items 1.01
same fact type: material_agreement
same SEC item: 1.01
same event type: litigation
similar materiality
This filing
On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”).
Comparable filing
On April 14, 2026, the Company entered into a Settlement Agreement (the “Agreement”) with respect to this civil action for such expected settlement amount, which resolves all claims related to this matter.
Filing page
SEC filing
CPT
Camden Property Trust settles RealPage antitrust class action for $53M
CAMDEN PROPERTY TRUST
April 9, 2026, 7:59 PM ET
litigation
Items 1.01, 7.01
same fact type: material_agreement
same SEC item: 1.01
same event type: litigation
similar materiality
This filing
On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”).
Comparable filing
On April 7, 2026, Camden Property Trust, on behalf of itself and related entities (collectively, the “Company”) entered into a binding term sheet for a settlement with the named plaintiffs in the Class Action Litigation, individually and on behalf of the class members (together, the “Plaintiffs”).
Filing page
SEC filing
SLND
Southland subsidiary settles WA convention center lawsuit; sureties to pay additional $26.5M
Southland Holdings, Inc.
April 2, 2026, 7:59 PM ET
litigation
Items 1.01
same fact type: material_agreement
same SEC item: 1.01
same event type: litigation
similar materiality
This filing
On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”).
Comparable filing
On March 27, 2026, American Bridge Company (“American Bridge”), a wholly owned subsidiary of Southland Holdings, Inc. (the “Company”), entered into a Settlement Agreement and Release of Claims (the “Settlement Agreement”) with Clark/Lewis, a Joint Venture (“Clark/Lewis”), certain sureties of American Bridge (the “Sureties”), the Washington State Convention Center (“WSCC”), and American Bridge’s litigation counsel.
Filing page
SEC filing
ICCC
ImmuCell settles Norbrook dispute, to receive $2M payment
IMMUCELL CORP /DE/
May 8, 2026, 7:59 PM ET
litigation
Items 1.01
same fact type: material_agreement
same SEC item: 1.01
same event type: litigation
This filing
On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”).
Comparable filing
On May 8, 2026, ImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims arising out of or relating to an underlying 2019 Development Services and Commercial Supply Agreement between the two companies.
Filing page
SEC filing
OPY
Oppenheimer settles cash-sweep class action for $70M, to impact Q1 earnings
OPPENHEIMER HOLDINGS INC
April 27, 2026, 7:59 PM ET
litigation
Items 1.01, 9.01
same fact type: material_agreement
same SEC item: 1.01
same event type: litigation
This filing
On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”).
Comparable filing
On April 24, 2026, Oppenheimer & Co., Inc. (“Oppenheimer”), the principal operating subsidiary of Oppenheimer Holdings Inc. (the “Company”), reached an agreement to settle the previously disclosed litigation styled Liberty Capital Group, Individually and on Behalf of All Others Similarly Situated v. Oppenheimer Holdings Inc., Oppenheimer & Co. Inc., and Oppenheimer Asset Management Inc. , No. 1:25-cv04822-JSR which was filed in the United States District Court for the Southern District of New York in June of 2025 (the “ District Court”).
Filing page
SEC filing
MKTW
MarketWise settles arbitration with former CEO for $12.16M cash, redeems 520,867 units, terminates TRA rights
MARKETWISE, INC.
April 24, 2026, 7:59 PM ET
litigation
Items 1.01, 9.01
same fact type: material_agreement
same SEC item: 1.01
same event type: litigation
This filing
On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”).
Comparable filing
On April 21, 2026, Marketwise, Inc. (the “Company”) and its subsidiary, MarketWise, LLC (together with the Company, “MarketWise”), entered into a Settlement Agreement and Release (the “Settlement Agreement”) with Mark P. Arnold, the Company’s former Chief Executive Officer, and JAMA 2021, LLC (together with Mr. Arnold, the “Arnold Parties”).
Filing page
SEC filing
AGAE
Allied Gaming settles litigation with Knighted for ~$5.94M paid over 3 months; CEO Li personally guarantees payment
Allied Gaming & Entertainment Inc.
April 21, 2026, 7:59 PM ET
litigation
Items 1.01, 5.02, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01
same event type: litigation
This filing
On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”).
Comparable filing
On April 10, 2026, Allied Gaming & Entertainment Inc. (the “Company”) and Yangyang Li, its Chief Executive Officer and Chairman, in his personal capacity (“Mr. Li”, and together with the Company, the “Allied Parties”) entered into a binding Term Sheet for Global Resolution (the “Term Sheet”) with Knighted Pastures, LLC (“Knighted”) and Roy Choi, in his personal capacity (“Mr. Choi”, and together with Knighted, the “Knighted Parties”).
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.